As the first approved FcRn antagonist for treating MG, efgartigimod has a higher affinity to block FcRn in comparison to the competitive saturation from IVIg, which has been mainly shown in in vitro studies using transfected endothelial cells expressing human FcRn-GFP (27). The gene discussed is FCGRT; the disease is myasthenia gravis.